Patents Assigned to TESARO, Inc.
-
Patent number: 11926665Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.Type: GrantFiled: January 9, 2018Date of Patent: March 12, 2024Assignee: TESARO, INC.Inventors: Dmitri Bobilev, Andrew R. Ferguson, Kristen Anne McEachern, Jing Wang
-
Patent number: 11801240Abstract: The present disclosure relates to combination therapies containing one or more PARP inhibitors and one or more angiogenesis inhibitor. Also described herein are therapeutic uses of such combination therapies for treating various disorders and conditions. The combination therapies and uses thereof can be useful for preventing tumor cell growth, preventing tumor metastasis, inducing an immune response or enhancing an immune response.Type: GrantFiled: October 5, 2018Date of Patent: October 31, 2023Assignee: Tesaro, Inc.Inventors: Keith W. Mikule, Zebin Wang, Yinghui Zhou
-
Patent number: 11753472Abstract: Provided herein are anti-T Cell Immunoglobulin and Mucin Protein-3 (TIM 3) antibodies having particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences and methods of using the anti-TIM-3 antibodies to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.Type: GrantFiled: October 27, 2021Date of Patent: September 12, 2023Assignees: Tesaro, Inc., Anaptysbio, Inc.Inventors: David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
-
Patent number: 11730725Abstract: The present invention relates to pharmaceutical tablet compositions comprising the compound niraparib as an active pharmaceutical ingredient, suitable for oral administration as well as to methods for their preparation. Also described herein are tablet compositions containing niraparib formed by the disclosed methods, and therapeutic uses of such tablet compositions for treating various disorders and conditions.Type: GrantFiled: September 26, 2018Date of Patent: August 22, 2023Assignee: Tesaro, Inc.Inventors: Simon McGurk, Padma Narayan, Aleksandar Rajlic
-
Patent number: 11673877Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.Type: GrantFiled: June 4, 2021Date of Patent: June 13, 2023Assignees: Tesaro, Inc., Merck Sharp & Dohme Corp.Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
-
Patent number: 11661453Abstract: The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly[ADP-ribose] polymerase (PARP) signaling.Type: GrantFiled: September 28, 2018Date of Patent: May 30, 2023Assignee: Tesaro, Inc.Inventors: Keith W. Mikule, Kaiming Sun, Jing Yu Wang, Zebin Wang
-
Patent number: 11629137Abstract: Disclosed herein are methods and processes of preparing niraparib and pharmaceutically acceptable salts thereof, and intermediates and their salts useful for the synthesis of niraparib.Type: GrantFiled: October 29, 2021Date of Patent: April 18, 2023Assignee: Tesaro, Inc.Inventors: Alistair Stewart, Anthony Joseph Toto, Frank Xing Chen, George Wu
-
Patent number: 11622961Abstract: The present invention provides methods of treatment for cancer(s) through combination therapy with an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling and an agent that regulates activity within the tumor microenvironment.Type: GrantFiled: May 18, 2018Date of Patent: April 11, 2023Assignee: Tesaro, Inc.Inventors: Kaiming Sun, Jing Yu Wang, Zebin Wang
-
Publication number: 20220319704Abstract: Described herein are methods, systems, devices and computer program products for characterizing or identifying a type of cancer. Also described are methods of treating a characterized or identified chancer. For example, certain methods may be used to characterize a homologous recombination deficiency status of a cancer.Type: ApplicationFiled: May 6, 2020Publication date: October 6, 2022Applicant: TESARO, INC.Inventors: Bin FENG, Hailei ZHANG, Jaegil KIM
-
Patent number: 11407830Abstract: The present invention provides methods of administering certain PD-1 binding agents to patients having cancer. Dosage regimens for compositions comprising a PD-1 binding agent are also explicitly provided.Type: GrantFiled: January 9, 2018Date of Patent: August 9, 2022Assignee: Tesaro, Inc.Inventors: David Jenkins, Haley A Laken, Ellie Im, Allene Diaz, Sharon Lu
-
Patent number: 11161834Abstract: Disclosed herein are methods and processes of preparing niraparib and pharmaceutically acceptable salts thereof, and intermediates and their salts useful for the synthesis of niraparib.Type: GrantFiled: April 24, 2018Date of Patent: November 2, 2021Assignee: Tesaro, Inc.Inventors: Alistair Stewart, Anthony Joseph Toto, Frank Xing Chen, George Wu
-
Patent number: 11155624Abstract: The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.Type: GrantFiled: November 1, 2017Date of Patent: October 26, 2021Assignees: ANAPTYSBIO, INC., Tesaro, Inc.Inventors: David J. King, Marilyn Kehry, Baochuan Huang
-
Patent number: 11091459Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.Type: GrantFiled: September 26, 2019Date of Patent: August 17, 2021Assignees: Tesaro, Inc., Merck Sharp & Dohme Corp.Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
-
Patent number: 10829476Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.Type: GrantFiled: September 26, 2019Date of Patent: November 10, 2020Assignee: Tesaro, Inc.Inventors: George Wu, John Chaber
-
Publication number: 20200299387Abstract: The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.Type: ApplicationFiled: September 28, 2018Publication date: September 24, 2020Applicant: Tesaro, Inc.Inventors: Keith W. MIKULE, Kaiming SUN, Jing Yu WANG, Zebin WANG
-
Publication number: 20200289493Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.Type: ApplicationFiled: May 9, 2018Publication date: September 17, 2020Applicants: TESARO, Inc., MERCK SHARP & DOHME B.V.Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
